286
Participants
Start Date
March 10, 2021
Primary Completion Date
July 31, 2022
Study Completion Date
February 1, 2023
Lebrikizumab
Administered SC
Placebo
Administered SC
Topical Corticosteroid
Self-applied
Shirasaki Clinic, Takaoka-shi
Yanagihara dermatology clinic, Ainokawa, Ichikawa-shi
Kawashima Dermatology Clinic, Ichikawa-shi
Charme Clinique, Matsudo
Yasumoto Dermatology Clinic, Chikushino-shi
Hino Dermatology Clinic, Fukutsu
Hiroshima University Hospital, Hiroshima
Takagi Dermatology, Obihiro
Sapporo Skin Clinic, Sapporo
Kobayashi Skin Clinic, Sapporo
Dermatology Shimizu Clinic, Kobe
Ibaraki Medical Center, Inashiki-gun
KAJI Dermatology Clinic, Nonoichi-shi
Kosugi Dermatology Clinic, Kawasaki
Queen's Square Dermatology and Allergology, Nishi-ku, Yokohama-city
Nomura Dermatology Clinic, Yokohama
Noguchi Dermatology, Kashima-machi, Kamimashiki-gun
Jyouzanhihuka・Hinyoukika Clinic, Kumamoto
Osaka Habikino Medical Center, Habikino
Mochida Dermatology Clinic, Izumiotsu-shi
Kume Clinic, Sakai
Yoshikawa Dermatology Clinic, Takatsuki
Sanrui Dermatology Clinic, Ohmiya-ku,Saitama-shi
Dokkyo Medical University Hospital, Shimotsuga-Gun
Akihabara Skin Clinic, Chiyoda-ku
Sumire Dermatology Clinic, Edogawa-ku
Maruyama Dermatology Clinic, Koto-ku
Hamaguchi Skin Clinic, Machida-shi
Mita Dermatology Clinic, Minato-Ku
Tanpopo Dermatology Clinic, Ōta-ku
Yamate Dermatological Clinic, Shinjuku
Yoshihara Dermatology Clinic, Sumida-ku
Tachikawa Dermatology Clinic, Tachikawa-shi
Matsuda Tomoko Dermatological Clinic, Fukuoka
Kyoto Furitsu Medical University Hospital, Kyoto
Osaka City University Hospital, Osaka
Goto Dermatology Clinic, Osaka
Eli Lilly and Company
INDUSTRY